Chinese Company Says Its COVID-19 Vaccine Should Be Available in U.S. in Early 2021

Medical News
>
Critical Care
>
Chinese Company Says Its COVID-19 Vaccine Should Be Available in U.S. in Early 2021

modernClinician Editorial Team Posted September 24th

If it passes final round of human tests, SinoVac will apply to the FDA to sell CoronaVac vaccine

THURSDAY, Sept. 24, 2020 (HealthDay News) — A Chinese pharmaceutical company claims its COVID-19 vaccine should available by early next year for distribution in the United States and other countries.

If it passes its final round of human tests, SinoVac will apply to the U.S. Food and Drug Administration to sell the CoronaVac vaccine, company CEO Yin Weidong said Thursday, the Associated Press reported.

Tight rules in the United States, European Union, Japan, and Australia have historically blocked the sale of Chinese vaccines, but that could change, according to Yin.

“We are confident that our research of the COVID-19 vaccines can meet the standards of the U.S. and EU countries,” Yin said, the AP reported.

AP News Article